Clearside Biomedical Announces Organizational Changes Designed to Support Transition to a Commercial-Stage Company
Clearside expects to report topline data from its pivotal Phase 3 PEACHTREE clinical trial of suprachoroidal CLS-TA in this indication in the first quarter of 2018 and, if the final data are positive, anticipates filing a New Drug Application (“NDA”) with the
Mr. Humphries, who has served as a director of Clearside since
“Suprachoroidal CLS-TA for the treatment of non-infectious uveitis is our most advanced development program and we are approaching a potential inflection point for our company with the pending release of topline results from the PEACHTREE clinical trial this quarter,” said Clearside’s Chief Executive Officer and President,
“Christy Shaffer and the Hatteras team have been an inspiration in the initial 6 years of Clearside’s development, and I am both deeply honored to succeed Christy as Chair and incredibly energized by this opportunity to help Clearside potentially transition from a clinical-stage to a commercial-stage company,” commented Mr. Humphries.
Clearside also announced the appointment of
Mr. Raymond brings a wealth of ophthalmic experience and an extensive stakeholder network to Clearside. He has a track record of success building out commercial capabilities, leading marketing and sales teams, and cultivating strong thought leader relationships across multiple specialties. Prior to joining Clearside, Mr. Raymond managed a consulting firm that led multiple strategy projects for clinical-stage biotechnology companies. His 16 years of progressive healthcare experience includes commercial leadership roles with
“We are entering into a stage of potential rapid growth,” said Mr. White. “Brion’s experience brings a particularly relevant depth of knowledge of ophthalmic biopharmaceutical product launches and strong relationships in the retina community to Clearside. At Genentech, he was a key member of the team responsible for launching Lucentis, and we are thrilled to have an executive of his caliber join our team in this important new position.”
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include expectations regarding Clearside transitioning from a clinical-stage company to a commercial-stage company, the potential clinical development of Clearside’s product candidates, the timing of topline results from Clearside’s PEACHTREE trial, the timing of a potential filing of an NDA with the
Chief Financial Officer
Source: Clearside Biomedical, Inc.